key: cord-0948504-royubj03 authors: Southwick, Frederick S title: Improving the definition of COVID-19-related deaths date: 2021-05-17 journal: J Infect Dis DOI: 10.1093/infdis/jiab271 sha: 9f436c0228aa7c7501c96b99b5b217e53eeff930 doc_id: 948504 cord_uid: royubj03 nan The World Health Organization defines a COVID-19 death as "a death resulting from a clinically compatible illness in a probable or confirmed COVID-19 case." [1] The United Kingdom has modified this definition, requiring that a positive RTPCR test to have been performed within 28 days of death. [2] This revised definition has significantly lowered case fatality rates. In the United States, the Center for Disease Control has created two categories: a confirmed case or death defined by meeting confirmatory laboratory evidence of COVID-19 and a probable case or death that has epidemiologic and/or clinical criteria consistent with COVID-19 but is lacking confirmatory laboratory evidence for COVID-19. A number of states and regions are not reporting probable cases, thereby lowering the number of reported COVID-19 deaths. [3] Some infectious disease experts have expressed concern that the number of COVID-19 related deaths has been underestimated in the United States [4] and the World. [5] Differences in the availability of RTPCR testing, delays in the interval between testing and reporting results [6] as well as unexplained deaths outside of the hospital can all contribute to underdiagnosis. To work around the problem of insufficient testing, investigators have used excess all-cause mortality as a surrogate marker for U.S. COVID-19 deaths. Observations from March 1 to March 30, 2020 revealed the number of excess all-cause deaths was 28% higher than the official reports of COVID-19 deaths during the same period, supporting concerns that the COVID-19 death toll is underestimated. [6] A c c e p t e d M a n u s c r i p t and this diagnosis was included on their death certificate. If these individuals were excluded from the analysis specificity increased to 97.5%. Although this study has some limitations (absence of systematic postmortem testing, small numbers, different RTPCR test kits, and variations in nasopharyngeal sampling), these results are important and provide a more systematic approach for accurately measuring COVID-19 deaths. Postmortem RTPCR testing within 6 days of death is feasible and cost-effective and has the potential to eliminate the category of probable COVID-19 deaths. Postmortem testing will be particularly helpful for detecting COVID-19 deaths that take place outside of the hospital. Nursing home patients are a particular concern because COVID-19 manifestations are more difficult to detect. Increasing age is associated with a less robust immune response, blunting fever [7] and other manifestations of infection. [8] Impaired cognition may limit the ability to obtain an accurate history and clinical A c c e p t e d M a n u s c r i p t deterioration may be inadvertently attributed to underlying chronic diseases, rather than COVID-19. Postmortem testing for COVID-19 should be strongly considered in this population. As the pandemic recedes in the U.S.A., testing programs are likely to be dismantled and although postmortem coronavirus testing is a delayed measure of disease activity, consistent postmortem testing could serve as a backup method for detecting an unexpected surge in cases. Given the high sensitivity and specificity of this approach, the WHO and CDC should strongly consider including postmortem RTPCR SARS-CoV-2 testing as one of the key criteria for reporting COVID-19 deaths. A c c e p t e d M a n u s c r i p t WHO. Estimating mortality from COVID-19: Scientific Brief Covid-19: England comes into line with rest of UK on recording deaths About CDC COVID-19 Data No doubt' US has undercounted COVID-19 deaths. The Hill Death tolls of COVID-19: Where come the fallacies and ways to make them more accurate Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States Temperature Screening for SARS-CoV-2 in Nursing Homes: Evidence from Two National Cohorts Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility A c c e p t e d M a n u s c r i p t